Italia markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
278,53+0,04 (+0,02%)
In data: 11:34AM EST. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente278,49
Aperto278,99
Denaro279,19 x 800
Lettera279,35 x 900
Min-Max giorno277,50 - 279,94
Intervallo di 52 settimane211,71 - 329,72
Volume662.061
Media Volume2.815.649
Capitalizzazione149,271B
Beta (5 anni mensile)0,62
Rapporto PE (ttm)22,28
EPS (ttm)12,50
Prossima data utili25 apr 2024 - 29 apr 2024
Rendimento e dividendo (futuro)9,00 (3,23%)
Data ex dividendo15 feb 2024
Stima target 1A307,59
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

    Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery